中药与常规疗法治疗儿童过敏性紫癜性肾炎:随机对照试验研究方案
本研究为在中国开展的多中心、开放标签、大样本随机对照试验,纳入500例病理表现轻微的过敏性紫癜性肾炎(HSPN)患儿,治疗组与对照组按2:1比例分组,并按尿蛋白定量和病理类型分为轻、重两型。治疗组接受雷公藤多苷、丹参酮Ⅱa磺酸钠注射液及辨证中药,对照组轻症用盐酸贝那普利片、低分子量肝素钙注射液、双嘧达莫片及中药安慰剂,重症加用泼尼松;所有组治疗3个月后随访9个月,评估疗效与安全性。
要点
- 针对病理分级1-3级、持续蛋白尿未达肾病水平或血尿的HSPN患儿,现有治疗可能不足。
- 中药整合治疗方案包括雷公藤多苷、丹参酮Ⅱa磺酸钠注射液及辨证中药。
- 研究为多中心、开放标签、大样本随机对照试验,治疗3个月随访9个月。
核心结论
- 本研究旨在评估中药整合治疗方案对病理表现轻微的HSPN患儿的疗效与安全性,为该类患者提供新的治疗思路。
研究设计与样本
- 多中心、开放标签、大样本随机对照试验,在中国开展,纳入500例病理表现轻微的HSPN患儿,治疗组与对照组比例为2:1,并按尿蛋白定量和病理类型分为轻、重两型。
主要发现
- 原文未报告研究结果。
关键数值与推荐
- 治疗组接受雷公藤多苷(TG)、丹参酮Ⅱa磺酸钠注射液及辨证中药,重型和轻型亚组接受不同疗程和剂量的TG。
- 对照组轻症接受盐酸贝那普利片、低分子量肝素钙注射液、双嘧达莫片及中药安慰剂;重症接受相同治疗加泼尼松。
- 所有组治疗3个月,随后随访9个月。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. Currently, the treatment for HSPN is always selected based on the Kidney Disease Improving Global Outcomes guidelines; however, this approach may lead to undertreatment, especially in patients with persistent proteinuria that does not reach nephrotic levels and/or hematuria and those with a pathological classification between grades 1 and 3 according to the International Study of Kidney Disease in Children. This study was performed to evaluate the curative effect and safety of a traditional Chinese medicine (TCM) integrated treatment program in this type of HSPN. METHODS: This multicenter, open-label, large-sample, randomized controlled trial was performed in China and included 500 children with HSPN exhibiting mild pathological patterns. The treatment group to control group ratio was 2:1, and each group was further stratified into two types, light and heavy, according to urinary protein quantification and pathological type. The treatment group received tripterygium glycosides (TGs), tanshinone IIa sodium sulfonate injection, and Chinese herbs selected based on syndrome differentiation in TCM. The heavy and light subgroups received treatment courses and dosages of TG. In the control groups, the light group received benazepril hydrochloride tablets, low molecular weight heparin calcium injection, dipyridamole tablets, and a Chinese medicine placebo, while the heavy group received the same treatment plus prednisone. All groups were treated for 3 months and then followed up for 9 months. The efficacy and safety of the treatments were then evaluated among the groups. DISCUSSION: Currently, few treatments are available for HSPN patients with mild pathological patterns indicating light to moderate proteinuria and/or hematuresis. In this large-sample study, we provide a new approach for HSPN that includes an integrated treatment program that incorporates TCM. TRIAL REGISTRATION: Clinical Trials.gov, NCT03591471 . Re-registered on 19 July 2018.
引用
- Ding Y, Zhang X, Ren X, et al. Traditional Chinese medicine versus regular therapy in Henoch-Schönlein purpura nephritis in children: study protocol for a randomized controlled trial. Trials. 2019. PMID: 31464626. doi:10.1186/s13063-019-3484-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。